Dance Biopharm unveils positive Phase 2 trial data for inhaled insulin
Category: #health  By Mateen Dalal  Date: 2019-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Dance Biopharm unveils positive Phase 2 trial data for inhaled insulin

The new data further supports the potential of Dance 501 inhaled insulin in Type 2 diabetes patients

Dance Biopharm Holdings, Inc has recently presented Phase 2 Samba 04 clinical study results for its preservative free inhaled human insulin, Dance 501, for the treatment of Type 2 diabetes. Dance Biopharm is a privately-owned clinical stage biopharma company fully focused on the development of a new soft mist inhalable biologic formulations for those people suffering from chronic diseases.

Seemingly, in the results Dance 501 showed a faster onset of action for as compared to similar doses of subcutaneously administered insulin lispro. These findings were to be presented at the 79th Scientific Sessions of the American Diabetes Association, being organized in San Francisco.

According to Anne Whitaker, the chief executive officer of Dance Biopharm, the company’s presentation at ADA underscores ongoing commitment of Dance to develop advanced and patient-focused inhaled therapies that result to better health outcomes for people suffering with chronic diseases like diabetes.

Whitaker said that the new data further supports the potential of Dance 501, inhaled preservative free human inhaled insulin, which is an alternate treatment to injectable insulin for diabetes. These data determine the outstanding performance of soft mist inhaler platform and encourages the company to swiftly progress the development of its innovative soft mist biologics portfolio as treatments for chronic and severe diseases, Whitaker mentioned.

Sources familiar with the matter informed that this Phase 2 clinical trial, Samba 04, was designed as an open label, crossover, randomized, and active-comparator-controlled study that recruited 24 subjects with type 2 diabetes presently receiving metformin or insulin therapy. Each patient got three doses of subcutaneous insulin lispro and three doses of inhaled Dance 501 under medical administration or supervision.

Apparently, doses administered were 12, 24 and 48 U for both lispro and Dance 501. Each patient received all 6 doses during 6 visits that occurred 3 to 17 days apart. Using the automated glucose clamp method, insulin action was measured over a 10-hour period following dosing.

 

Source Credit: https://www.dancebiopharm.com/investors-and-media/press-releases/detail/18/dance-biopharm-presents-encouraging-data-from-phase-2

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Peraton to acquire innovative IT solutions provider Solers Inc.
Peraton to acquire innovative IT solutions provider Solers Inc.
By Mateen Dalal

Virginia-based Peraton, a defense and intelligence contractor owned by private equity firm Veritas Capital, reportedly announced that it has signed a definitive agreement to acquire Solers Inc., a leading provider of software development and cybersec...

Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
Forty Seven publishes data on Phase 1b/2 clinical trial of 5F9
By Mateen Dalal

A clinical-stage immune-oncology company, Forty Seven, Inc., that works to develop therapies targeting cancer immune evasion pathways, has revealed clinical data from Phase 1b/2. The company is evaluating a new drug combination of Recombinant Human A...

FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
FDA grants orphan drug tag to NuCana’s biliary tract cancer treatment
By Mateen Dalal

NuCana is on its way to open a Global Phase III study of Acelarin in combination with cisplatin for patients who are suffering from the disease in 2019 NuCana plc recently announced that it has received Orphan Drug Designation for Acelarin, an inves...